Zacks Investment Research upgraded shares of Innate Pharma (NASDAQ:IPHA) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “

A number of other analysts have also commented on the company. Svb Leerink reissued an outperform rating on shares of Innate Pharma in a report on Monday, November 11th. HC Wainwright reissued a buy rating on shares of Innate Pharma in a report on Tuesday, November 26th.

Shares of Innate Pharma stock traded down $0.33 on Thursday, reaching $7.40. The company’s stock had a trading volume of 13,275 shares. The company’s fifty day moving average price is $7.15. Innate Pharma has a 52 week low of $5.61 and a 52 week high of $8.24.

An institutional investor recently bought a new position in Innate Pharma stock. Oxford Asset Management LLP acquired a new position in Innate Pharma S.A. (NASDAQ:IPHA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 44,226 shares of the company’s stock, valued at approximately $284,000. Oxford Asset Management LLP owned 0.06% of Innate Pharma at the end of the most recent reporting period.

Innate Pharma Company Profile

Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

Featured Article: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Innate Pharma (IPHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.